Quince Therapeutics, Inc. (CRTX) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

ImmunoPrecise Antibodies Ltd.

ImmuCell Corp.

Marker Therapeutics, Inc.

HOOKIPA Pharma, Inc.

Cognition Therapeutics, Inc.

VistaGen Therapeutics, Inc.

Quince Therapeutics, Inc.

Gain Therapeutics, Inc.

Mainz Biomed NV

Viracta Therapeutics, Inc.

CytoMed Therapeutics Ltd.

Why is Quince Therapeutics, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Quince Therapeutics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Quince Therapeutics, Inc.

66.67%

3.41

73.57%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

5.46%

EBIT to Interest (avg)

-54.25

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.87

Sales to Capital Employed (avg)

Tax Ratio

0.17%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

19.48%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.86

EV to EBIT

-0.91

EV to EBITDA

-0.92

EV to Capital Employed

15.73

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-1720.47%

ROE (Latest)

-206.93%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company

NET PROFIT(HY)

Higher at USD -22.34 MM

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -146.73 %

-14What is not working for the Company

NET PROFIT(HY)

At USD -22.34 MM has Grown at -63.32%

OPERATING CASH FLOW(Y)

Lowest at USD -35.83 MM

ROCE(HY)

Lowest at -167.04%

CASH AND EQV(HY)

Lowest at USD 66.31 MM

Here's what is working for Quince Therapeutics, Inc.

Net Profit

Higher at USD -22.34 MM

than preceding 12 month period ended Jun 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Debt-Equity Ratio

Lowest at -146.73 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Quince Therapeutics, Inc.

Net Profit

At USD -22.34 MM has Grown at -63.32%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Cash Flow

Lowest at USD -35.83 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Cash and Eqv

Lowest at USD 66.31 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents